Ex Vivo Model to Assess the Exposure of Patients to Plasticizers from Medical Devices during Pre-CAR-T Cells' Apheresis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35202265/
doi: 10.3390/toxics10020079. 1 Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France. 2 CHU Clermont-Ferrand, Centre de Biothérapie d'Auvergne, F-63000 Clermont-Ferrand, France. 3 Université Clermont...
Conclusions: Patients undergoing a pre-CAR-T cell apheresis are mainly exposed to DEHP, which can impact their health because of its endocrine disruption effect, but could also lead to a decrease in CAR-T cells' efficiency/quality.
Research progress in overcoming ibrutinib drug resistance
Drugs of Today Drugs Today 2022, 58(2): 85ISSN 1699-3993Copyright 2022 ClarivateCCC: 1699-3993DOI: 10.1358/dot.2022.58.2.3360405 Research progress in overcoming ibrutinib drug resistance Ma, X.-Y., Zhao, M., Li, Y.-D., Chen, Y., Wei, L.,...
Expert opinion: Navigating this scenario, will uncover new challenges, including identifying an ideal sequence for these therapies, the most effective combinations, and search for consistent predictive factors to help selecting the appropriate population of LBCL patients. At present, supporting clinical research for CAR-T ineligible patients,...
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: an expert panel opinion statement - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35212014/
The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as...
Relevance: This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence. This article is protected by copyright. All rights reserved.
Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors
Covalent (irreversible) Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired mutations...
Conclusions: Resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream PLCγ2 mutations that allowed escape from BTK inhibition. A proportion of these mutations also conferred resistance across clinically approved covalent BTK inhibitors. These data suggested new mechanisms of genomic escape from...
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35002256/
In chronic lymphocytic leukemia (CLL), a deeper understanding of the disease biology led over the last decade to the development and clinical use of different targeted drugs, including Bruton tyrosine...
Conclusion: Due to its efficacy and the favorable safety profile, acalabrutinib has emerged as a viable therapy option in the current landscape of multiple approved treatments for CLL.